Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Familial platelet disorder with predisposition to acute myelogenous leukaemia (FPD/AML, MIM 601399) is an autosomal dominant disorder characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukaemia (AML). Informative recombination events in 6 FPD/AML pedigrees with evidence of linkage to markers on chromosome 21q identified an 880-kb interval containing the disease gene. Mutational analysis of regional candidate genes showed nonsense mutations or intragenic deletion of one allele of the haematopoietic transcription factor CBFA2 (formerly AML1) that co-segregated with the disease in four FPD/AML pedigrees. We identified heterozygous CBFA2 missense mutations that co-segregated with the disease in the remaining two FPD/AML pedigrees at phylogenetically conserved amino acids R166 and R201, respectively. Analysis of bone marrow or peripheral blood cells from affected FPD/AML individuals showed a decrement in megakaryocyte colony formation, demonstrating that CBFA2 dosage affects megakaryopoiesis. Our findings support a model for FPD/AML in which haploinsufficiency of CBFA2 causes an autosomal dominant congenital platelet defect and predisposes to the acquisition of additional mutations that cause leukaemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The transcription factor RUNX-1 plays a key role in megakaryocyte differentiation and is mutated in cases of myelodysplastic syndrome and leukemia.”
From Differentiation-dependent interactions between RUNX-1 and FLI-1 during megakaryocyte development. (2009) · cites this paper as [48]
In the citing paper
“Germ line mutations in RUNX-1 cause familial platelet disorder with the propensity to develop acute myelogenous leukemia (FPD/AML), a rare autosomal dominant disorder characterized by quantitative and qualitative platelet defects and a high incidence of developing myelodysplastic syndrome (MDS) and leukemia”
From Differentiation-dependent interactions between RUNX-1 and FLI-1 during megakaryocyte development. (2009) · cites this paper as [48]
Citations
Cites
Okuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., & Downing, J. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80986-1 · Cited by 1,856
de Thé, H., Chomienne, C., Lanotte, M., Degos, L., & Dejean, A. (1990) · Nature · doi:10.1038/347558a0 · Cited by 1,355 · cited 1×
“Fusion of PDGF Receptor β to a novel ETS-like gene, TEL, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.”
BackgroundWang, Q., Stacy, T., Binder, M., Marin-Padilla, M., Sharpe, A. H., & Speck, N. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3444 · Cited by 1,178
Self-citationGolub, T. R., Barker, G. F., Lovett, M., & Gilliland, D. G. (1994) · Cell · doi:10.1016/0092-8674(94)90322-0 · Cited by 1,155
Self-citationOncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis.
Weinberg, R. A. (1989) · PubMed · Cited by 949
The murine gene p27Kip1 is haplo-insufficient for tumour suppression
Fero, M. L., Randel, E., Gurley, K. E., Roberts, J. M., & Kemp, C. J. (1998) · Nature · doi:10.1038/24179 · Cited by 784
Fusion Between Transcription Factor CBFβ/PEBP2β and a Myosin Heavy Chain in Acute Myeloid Leukemia
Liu, P., Tarlé, S. A., Hajra, A., Claxton, D. F., Marlton, P., Freedman, M., Siciliano, M. J., & Collins, F. S. (1993) · Science · doi:10.1126/science.8351518 · Cited by 732 · cited 1×
“; the CBFB / MYH11 fusion associated with inv(16) myelomonocytic leukaemia with eosinophili”
BackgroundFusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia.
Golub, T. R., Barker, G. F., Bohlander, S. K., Hiebert, S. W., Ward, D. C., Bray-Ward, P., Morgan, E., Raimondi, S. C., Rowley, J. D., & Gilliland, D. G. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.4917 · Cited by 704
Self-citationShivdasani, R. A., Rosenblatt, M. F., Zucker-Franklin, D., Jackson, C. W., Hunt, P., Saris, C. J. M., & Orkin, S. H. (1995) · Cell · doi:10.1016/0092-8674(95)90531-6 · Cited by 693 · cited 1×
“It is notable that mice hemizygous for genes required for megakaryopoiesis, such as Gata1 , Nfe2 and fog , have apparent platelet defect”
BackgroundShivdasani, R. A., Fujiwara, Y., McDevitt, M. A., & Orkin, S. H. (1997) · The EMBO Journal · doi:10.1093/emboj/16.13.3965 · Cited by 674 · cited 1×
“It is notable that mice hemizygous for genes required for megakaryopoiesis, such as Gata1 , Nfe2 and fog , have apparent platelet defect”
Background
Cited by
Items 501–600 of 1,000
Bcl-xL and Akt cooperate to promote leukemogenesis in vivo
Karnauskas, R., Niu, Q., Talapatra, S., Plas, D. R., Greene, M. E., Crispino, J. D., & Rudin, C. M. (2003) · Oncogene · doi:10.1038/sj.onc.1206159 · Cited by 38
“…of a number of tumor-suppressor genes that have a haploinsufficient phenotype: such critical loci would be missed entirely by most physical mapping approaches, as in the hemizygous state the remaining allele retains a wild-type sequence (Barlow et al., 1999; Komuro et al., 1999; Song et al., 1999).”
BackgroundZezulin, A. U., Yen, D. P., Howell, E., Yen, D., Bresciani, E., Diemer, J. L., Ren, J., Ahmad, M. H., Castilla, L. H., Touw, I. P., et al. (2023) · Genes & Development · doi:10.1101/gad.350418.123 · Cited by 35
Self-citationNakao, M., Horiike, S., Fukushima‐Nakase, Y., Nishimura, M., Fujita, Y., Taniwaki, M., & Okuda, T. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04966.x · Cited by 34
“Similarly, affected family members of FPD/AML pedigree with a haplo-insufficient AML1 allele generally have 20–40 years of latency prior to development of overt leukaemia (Song et al, 1999; Buijs et al, 2001; Michaud et al, 2002; Walker et al, 2002).”
BackgroundNormal and malignant megakaryopoiesis
Wen, Q., Goldenson, B., & Crispino, J. D. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411002043 · Cited by 43
Inherited thrombocytopenias: an approach to diagnosis and management
Geddis, A. E. (2012) · International Journal of Laboratory Hematology · doi:10.1111/j.1751-553x.2012.01454.x · Cited by 37
“Heterozygous mutations of RUNX1 described in FPD-PMM range from substitutions or large deletions.”
BackgroundInfluentialZebrafish Cancer Predisposition Models
Kobar, K., Collett, K., Prykhozhij, S. V., & Berman, J. N. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.660069 · Cited by 40
Dynamic Runx1 chromatin boundaries affect gene expression in hematopoietic development
Owens, D. D. G., Anselmi, G., Oudelaar, A. M., Downes, D. J., Cavallo, A., Harman, J. R., Schweßinger, R., Bucakci, A., Greder, L. V., Ornellas, S. D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28376-8 · Cited by 37
“Runx1 transcription is tightly regulated, with changes in gene dosage and expression level affecting both the spatiotemporal onset of hematopoiesis and hematopoietic homeostasis (Cai et al. 2000, Lie et al. 2018, Song et al. 1999, Wang Q. et al. 1996).”
BackgroundPotts, K. S., Sargeant, T., Dawson, C. A., Josefsson, E. C., Hilton, D. J., Alexander, W. S., & Taoudi, S. (2015) · Blood · doi:10.1182/blood-2014-12-616607 · Cited by 34
The role of Runx1/AML1 and Evi‐1 in the regulation of hematopoietic stem cells
Kumano, K., & Kurokawa, M. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21953 · Cited by 37
Wu, D., Luo, X., Feurstein, S. K., Kesserwan, C. A., Mohan, S., Álvarez, D. E. P., & Godley, L. A. (2020) · Haematologica · doi:10.3324/haematol.2018.214221 · Cited by 35
“Subsequent linkage analysis identified RUNX1 as the candidate gene at chromosome 21q22,(11) and mutations were detected in FPD/AML families in 1999.(11) Since these initial early reports, routine clinical testing for RUNX1 gene mutations is now commonplace for the evaluation of somatic and germline disease in patients…”
BackgroundMolecular basis for a dominant inactivation of RUNX1/AML1 by the leukemogenic inversion 16 chimera
Huang, G., Shigesada, K., Wee, H., Liu, P. P., Osato, M., & Ito, Y. (2003) · Blood · doi:10.1182/blood-2003-07-2188 · Cited by 36
Myelodysplastic syndromes: recent advances.
Alessandrino, E. P., Amadori, S., Cazzola, M., Locatelli, F., Mecucci, C., Morra, E., Saglio, G. N., Visani, G., & Tura, S. (2001) · PubMed · Cited by 34
Update on the causes of platelet disorders and functional consequences
Freson, K., Wijgaerts, A., & Geet, C. V. (2014) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12213 · Cited by 33
“2014, 36, 313–325 addition to thrombocytopenia, platelets in FPD-AML are dysfunctional, with abnormalities evident in aggregation and ATP release assays [9].”
BackgroundInfluentialPin1‐mediated Runx2 modification is critical for skeletal development
Yoon, W., Islam, R., Cho, Y., Woo, K. M., Baek, J., Uchida, T., Komori, T., van Wijnen, A. J., Stein, J. L., Lian, J. B., et al. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24403 · Cited by 33
“Indeed, changes in the gene dosage of most Runt-related transcription factors are a common regulatory mechanism in the pathogenesis of many human diseases, including cancer (Osato et al., 1999; Song et al., 1999) and sex determination of fruit fly (Duffy and Gergen, 1991).”
BackgroundChurpek, J. E., Garcia, J. S., Madžo, J., Jackson, S. A., Onel, K., & Godley, L. A. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.503821 · Cited by 33
“Dashed lines represent nonsense mutations, [6,7,9] and dotted lines indicate frameshift mutations [3,5–9].”
BackgroundMinelli, A., Maserati, E., Rossi, G., Bernardo, M. E., Stefano, P. D., Cecchini, M. P., Valli, R., Albano, V., Pierani, P., Leszl, A., et al. (2004) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20030 · Cited by 33
“Other families with FPD/AML have subsequently been described, with a total of 12 pedigrees reported so far (Gerrard et al., 1991; Arepally et al., 1998; Song et al., 1999; Buijs et al., 2001; Michaud et al., 2002; Walker et al., 2002).”
BackgroundMethodInfluentialChromosome 21: from sequence to applications
Antonarakis, S. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00185-4 · Cited by 32
Rodríguez, S., Torres-Ruiz, R., Suela, J., Acquadro, F., Martin, M. C., Yebra, E., Ramírez, J. C., Álvarez, S., & Cigudosa, J. C. (2015) · Oncogene · doi:10.1038/onc.2015.70 · Cited by 34
Harada, Y., Inoue, D., Ding, Y., Imagawa, J., Doki, N., Matsui, H., Yahata, T., Matsushita, H., Ando, K., Sashida, G., et al. (2013) · Blood · doi:10.1182/blood-2012-06-434423 · Cited by 34
“Germ line mutations of RUNX1 have been shown to occur in FPD/AML.(1,2) FPD/AML is regarded as familial MDS,(3) and the molecular mechanisms by which RUNX1 mutations promote the development of hematopoietic malignancies seem to be identical in both MDS and FPD/AML patients.”
BackgroundSakurai, M., Kasahara, H., Yoshida, K., Yoshimi, A., Kunimoto, H., Watanabe, N., Shiraishi, Y., Chiba, K., Tanaka, H., Harada, Y., et al. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2015.81 · Cited by 32
DiFilippo, E. C., Coltro, G., Carr, R. M., Mangaonkar, A. A., Binder, M., Khan, S. P., Rodriguez, V., Gangat, N., Wolanskyj, A. P., Pruthi, R. K., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0752-x · Cited by 32
Estevez, B., Borst, S., Jarocha, D. J., Sudunagunta, V. S., Gonzalez, M. V., Garifallou, J. P., Hakonarson, H. H., Gao, P., Tan, K., Liu, P., et al. (2021) · Blood · doi:10.1182/blood.2020006389 · Cited by 33
Self-citationGermline predisposition to hematopoietic malignancies
Feurstein, S. K., Drazer, M. W., & Godley, L. A. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab141 · Cited by 32
Buijs, A., Poot, M., van der Crabben, S. N., van der Zwaag, B., van Binsbergen, E., van Roosmalen, M. J., Tavakoli‐Yaraki, M., de Weerdt, O., Nieuwenhuis, H. K., van Gijn, M. E., et al. (2012) · Leukemia · doi:10.1038/leu.2012.79 · Cited by 32
Increased Dosage of the RUNX1/AML1 Gene: A Third Mode of RUNX Leukemia?
Osato, M., & Ito, Y. (2005) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukargeneexpr.v15.i3.40 · Cited by 37
Myeloid neoplasms with germ line RUNX1 mutation
Hayashi, Y., Harada, Y., Huang, G., & Harada, H. (2017) · International Journal of Hematology · doi:10.1007/s12185-017-2258-5 · Cited by 35
“Heterozygous germ line mutation in the RUNX1 gene is obviously a cause of FPD/AML [9].”
BackgroundInfluentialHamilton, K. V., Maese, L. D., Marron, J. M., Pulsipher, M. A., Porter, C. C., & Nichols, K. E. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00181 · Cited by 32
Cell-Autonomous Function of Runx1 Transcriptionally Regulates Mouse Megakaryocytic Maturation
Pencovich, N., Jaschek, R., Dicken, J., Amit, A. S., Lotem, J., Tanay, A., & Groner, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064248 · Cited by 31
“RUNX1 transcription factor (TF) is a key regulator of megakaryocytic development and when mutated is associated with familial platelet disorder and predisposition to acute myeloid leukemia (FPD-AML).”
BackgroundInfluentialLoss of AML1/Runx1 accelerates the development of MLL-ENL leukemia through down-regulation of p19ARF
Nishimoto, N., Arai, S., Ichikawa, M., Nakagawa, M. M., Goyama, S., Kumano, K., Takahashi, T., Kamikubo, Y., Imai, Y., & Kurokawa, M. (2011) · Blood · doi:10.1182/blood-2010-10-315440 · Cited by 35
Oved, J. H., Lambert, M. P., Kowalska, M. A., Poncz, M., & Karczewski, K. J. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15113 · Cited by 31
Self-citationTrottier, A. M., & Godley, L. A. (2020) · British Journal of Haematology · doi:10.1111/bjh.17247 · Cited by 31
Targeting RUNX1 in acute myeloid leukemia: preclinical innovations and therapeutic implications
Gonzales, F., Barthélémy, A., Peyrouze, P., Fenwarth, L., Preudhomme, C., Duployez, N., & Cheok, M. H.-C. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1915991 · Cited by 43
Muratoglu, S. C., Garratt, B., Hyman, K., Gajewski, K. M., Schulz, R. A., & Fossett, N. (2006) · Developmental Biology · doi:10.1016/j.ydbio.2006.04.455 · Cited by 35
Draper, J. E., Sroczyńska, P., Leong, H. S., Fadlullah, M. Z. H., Miller, C. J., Kouskoff, V., & Lacaud, G. (2017) · Blood · doi:10.1182/blood-2016-06-723635 · Cited by 34
The role of chromosome 21 in hematology and oncology
Fonatsch, C. (2010) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20764 · Cited by 30
“Besides the somatic RUNX1 mutations, germline mutations have been found in families with thrombocytopenia with predisposition to leukemia development (Song et al., 1999; Table 10).”
BackgroundJalagadugula, G. S., Mao, G., Kaur, G., Dhanasekaran, D. N., & Rao, A. K. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.221879 · Cited by 35
Runx1 Structure and Function in Blood Cell Development
Bonifer, C., Levantini, E., Kouskoff, V., & Lacaud, G. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-3233-2_5 · Cited by 31
Chisholm, K. M., Denton, C. C., Keel, S., Geddis, A. E., Xu, M., Appel, B., Cantor, A. B., Fleming, M. D., & Shimamura, A. (2019) · Pediatric and Developmental Pathology · doi:10.1177/1093526618822108 · Cited by 33
Molecular basis of inherited thrombocytopenias
Savoia, A. (2015) · Clinical Genetics · doi:10.1111/cge.12607 · Cited by 36
“Then, the immature cells undergo endomitosis, a hallmark of the maturation process, accumulating DNA up to a content of 128n.”
BackgroundInfluentialYoshimi, A., Toya, T., Nannya, Y., Takaoka, K., Kirito, K., Ito, E., Nakajima, H., Hayashi, Y., Takahashi, T., Moriya‐Saito, A., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw066 · Cited by 30
Mechanism of ETV6-RUNX1 Leukemia
Sundaresh, A., & Williams, O. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-3233-2_13 · Cited by 30
Nurden, A. T., & Nurden, P. (2007) · Haematologica · doi:10.3324/haematol.11256 · Cited by 35
A leukemia fusion protein attenuates the spindle checkpoint and promotes aneuploidy
Boyapati, A., Yan, M., Peterson, L. F., Biggs, J. R., Beau, M. M. L., & Zhang, D. (2006) · Blood · doi:10.1182/blood-2006-09-045583 · Cited by 34
Optimizing therapy for myeloid disorders of Down syndrome
Webb, D. K. H. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05700.x · Cited by 30
“1–22.2), a partner in several leukaemia translocations implicated in acute lymphoblastic leukaemia, AML and MDS is situated within the critical region for DS (21q22), and has a role in megakaryocyte differentiation (Song et al, 1999), but has no proven role in ML-DS.”
BackgroundInfluentialRe-envisioning genetic predisposition to childhood and adolescent cancers
Kratz, C. P. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00775-7 · Cited by 31
Next-Generation Sequencing of Cancer Genomes: Back to the Future
Walter, M. J., Graubert, T. A., DiPersio, J. F., Mardis, E. R., Wilson, R. K., & Ley, T. J. (2009) · Personalized Medicine · doi:10.2217/pme.09.52 · Cited by 31
“The best-characterized familial leukemia syndrome is the familial platelet disorder with a predisposition to AML (FDP/AML), which is caused by inherited mutations in RUNX1 [39].”
BackgroundInfluentialMyeloid neoplasms and clonal hematopoiesis from the RUNX1 perspective
Hayashi, Y., Harada, Y., & Harada, H. (2022) · Leukemia · doi:10.1038/s41375-022-01548-7 · Cited by 31
“Song et al. also identified germline RUNX1 mutations as the causal abnormality in familial platelet disorder with propensity to AML (FPD/AML) pedigrees [63].”
BackgroundInfluentialThe Clinical Spectrum, Diagnosis, and Management of GATA2 Deficiency
Santiago, M., Liquori, A., Such, E., Zúñiga, Á., & Cervera, J. (2023) · Cancers · doi:10.3390/cancers15051590 · Cited by 29
“Familial myelodysplastic syndromes (MDSs) and acute myeloid leukemia (AML), also known as hereditary myeloid malignancy syndromes (HMMSs), have been recognized phenotypically for more than a century, with the first molecular basis discovered in 1999 through the identification of germline RUNX1 mutations [1].”
BackgroundPina, C., & Enver, T. (2007) · Oncogene · doi:10.1038/sj.onc.1210759 · Cited by 39
“Dosage-dependent effects of RUNX1 are also observed in adult human haematopoiesis: haploinsufficiency of RUNX1 associates with an autosomal dominant form of familial thrombocytopenia with increased predisposition to development of AML (Song et al., 1999).”
Myelodysplastic/myeloproliferative neoplasms
Hyjek, E. M., & Vardiman, J. W. (2011) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2011.07.002 · Cited by 30
Tober, J. M., Maijenburg, M. W., & Speck, N. A. (2016) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2016.01.008 · Cited by 31
Self-citationRujkijyanont, P., Beyene, J., Wei, K., Khan, F., & Dror, Y. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06608.x · Cited by 29
Lineage-specific defect in gene expression in human platelet phospholipase C-β2 deficiency
Mao, G. F., Vaidyula, V. R., Kunapuli, S. P., & Rao, A. K. (2002) · Blood · doi:10.1182/blood.v99.3.905 · Cited by 29
SLC22A4 and RUNX1: identification of RA susceptible genes
Yamada, R., Tokuhiro, S., Chang, X., & Yamamoto, K. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0547-y · Cited by 30
“[42] of the RUNX1 gene are known to be causative”
BackgroundThe Role of Somatic Mutations in Acute Myeloid Leukemia Pathogenesis
Kishtagari, A., & Levine, R. L. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a034975 · Cited by 33
“Germline mutations in RUNX1 are associated with familial platelet disorder with propensity to myeloid malignancy (FPDMM), characterized by thrombocytopenia, platelet functional/ultrastructural defects, and a 20%–60% rate of transformation to overt myeloid malignancies (Song et al. 1999).”
BackgroundKumar, R., & Kahr, W. H. A. (2013) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.02.004 · Cited by 32
Malignant hematological disorders in children with Wolf–Hirschhorn syndrome
Sharathkumar, A. A., Kirby-Allen, M. A., Freedman, M. H., Abdelhaleem, M. M., Chitayat, D. A., Teshima, I. E., & Dror, Y. (2003) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.20080 · Cited by 28
“Genes associated with inherited syndromes and MDS are proven to be involved in de novo leukemogenesis such as core binding factor alpha-2 (CBFA2) in familial thrombocytopenia/AML syndrome [Roulston et al., 1998; Song et al., 1999].”
BackgroundMolecular Biology of Myelodysplastic Syndromes
Shih, A. H., & Levine, R. L. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.04.013 · Cited by 31
Romasko, E. J., Devkota, B., Biswas, S., Jayaraman, V., Rajagopalan, R., Dulik, M. C., Thom, C. S., Choi, J., Jairam, S., Scarano, M. I., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24917 · Cited by 29
TUBB 1 dysfunction in inherited thrombocytopenia causes genome instability
Matsumura, T., Nakamura‐Ishizu, A., Takaoka, K., Maki, H., Muddineni, S. S. N. A., Wang, C. Q., Suzushima, H., Kawakita, M., Asou, N., Matsuoka, M., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.15835 · Cited by 31
“Our findings and others related to RUNX1, another gene responsible for FPD/AML, suggest the superior competence of survival despite DNA damage accumulation can be a common critical feature of “pre-leukaemic” cells (Fig 6B, C). ª 2019 British Society for Haematology and John Wiley & Sons Ltd 899 British Journal of Haem…”
BackgroundInfluentialMolecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations
Harada, Y., & Harada, H. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22974 · Cited by 31
Speight, B., Hanson, H., Turnbull, C., Hardy, S. A., Drummond, J., Khorashad, J. S., Wragg, C., Page, P., Parkin, N. W., Rio‐Machín, A., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.18675 · Cited by 27
Transcription factor GATA-1 and Down syndrome leukemogenesis
Muntean, A. G., Ge, Y., Taub, J. W., & Crispino, J. D. (2006) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500485810 · Cited by 33
“One prominent example of this group is mutations in RUNX1/ AML1, which are associated with familial platelet disorder with predisposition to AML (FPD/AML) [4].”
BackgroundMao, G., Goldfinger, L. E., Fan, D. C., Lambert, M. P., Jalagadugula, G. S., Freishtat, R. J., & Rao, A. K. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13619 · Cited by 29
Rowntree, C. J., Duke, V. M., Panayiotidis, P. G., Kotsi, P., Palmisano, G. L., Hoffbrand, A. V., & Foroni, L. (2002) · Leukemia · doi:10.1038/sj.leu.2402551 · Cited by 27
The Role of the AML1 Transcription Factor in Leukemogenesis
Lorsbach, R. B., & Downing, J. R. (2001) · International Journal of Hematology · doi:10.1007/bf02982058 · Cited by 28
Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: “To Be or Not to Be Acetylated”?
Stintzing, S., Kemmerling, R., Kiesslich, T., Alinger, B., Ocker, M., & Neureiter, D. (2011) · BioMed Research International · doi:10.1155/2011/214143 · Cited by 28
“Recently, experimental and clinical investigations revealed that epigenetic processes could play a key role in MDS and could be innovative targets for therapeutic approaches [14–18].”
BackgroundGenetic Predisposition to Myelodysplastic Syndrome in Clinical Practice
Schratz, K. E., & Dezern, A. E. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2019.10.002 · Cited by 26
Genomic characterization of the RUNX2 gene of Fugu rubripes
Eggers, J. H., Stock, M., Fliegauf, M., Vonderstraß, B., & Otto, F. (2002) · Gene · doi:10.1016/s0378-1119(02)00592-9 · Cited by 28
Hayward, C. P. M. (2003) · Current Opinion in Hematology · doi:10.1097/00062752-200309000-00007 · Cited by 26
Mouse models of acute promyelocytic leukemia
Pollock, J. L., Westervelt, P., Walter, M. J., Lane, A. A., & Ley, T. J. (2001) · Current Opinion in Hematology · doi:10.1097/00062752-200107000-00005 · Cited by 26
Redundant mechanisms driven independently by RUNX1 and GATA2 for hematopoietic development
Bresciani, E., Carrington, B., Yu, K., Kim, E. M., Zhen, T., Guzman, V. S., Broadbridge, E., Bishop, K. S., Kirby, M., Harper, U. L., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003969 · Cited by 25
“We believe that elucidating the mechanism of this RUNX1-independent hematopoiesis has far-reaching implications in developing therapeutics for acute myeloid leukemia with germline or somatic mutations in RUNX1.”
BackgroundSyndromes predisposing to leukemia are a major cause of inherited cytopenias in children
Gilad, O., Dgany, O., Noy‐Lotan, S., Krasnov, T., Yacobovich, J., Rabinowicz, R., Goldberg, T. A., Kuperman, A. A., Quider, A. A., Miskin, H., et al. (2022) · Haematologica · doi:10.3324/haematol.2021.280116 · Cited by 25
“Refractory cytopenia of childhood (RCC) is the most common form of MDS in children.7 In contrast to MDS in adults, pediatric MDS is more commonly associated with genetic predisposition.8 Genetic alterations in GATA2 and SAMD9L have emerged as the most common cause of inherited pediatric MDS.9 Familial platelet disorde…”
BackgroundSlovak, M. L., O'Donnell, M. R., Smith, D. D., & Gaal, K. K. (2009) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2009.04.013 · Cited by 25
“with a high probability for developing MDS/AML [11], as well as in 20e40% high-grade MDS or therapy-related MDS after alkylating agents [12e14].”
BackgroundInfluentialYoshimi, A., Trippett, T. M., Zhang, N., Chen, X., Penson, A. V., Arcila, M. E., Pichardo, J. D., Baik, J., Sigler, A. M., Harada, H., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1204-9 · Cited by 27
Myelodysplastic Syndromes (MDS)
Pleyer, L., Neureiter, D., Faber, V., & Greil, R. (2010) · Springer eBooks · doi:10.1007/978-3-211-79892-8_6 · Cited by 25
Voora, D., Rao, A. K., Jalagadugula, G. S., Myers, R. A., Harris, E. M., Ortel, T. L., & Ginsburg, G. S. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.08.021 · Cited by 25
“Loss of functionmutations in RUNX1 in humans (an autosomal dominant disorder named Familial Platelet Disorder with associated Myeloid Malignancy (Song et al., 1999a)) lead to defects in platelet function including agonist-induced aggregation, secretion, protein phosphorylation, and activation of…”
BackgroundInfluentialSilva, M. C. D. A., Krepischi, A. C. V., Kulikowski, L. D., Zanardo, É. A., Nardinelli, L., Leal, A., da Costa, S. S., Muto, N. H., Rocha, V., & Velloso, E. D. R. P. (2018) · Cancer Genetics · doi:10.1016/j.cancergen.2018.01.002 · Cited by 24
Germline mutations in MDS/AML predisposition disorders
Godley, L. A. (2020) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000633 · Cited by 24
“(i) Germline RUNX1 mutations/familial platelet disorder (OMIM 151385, 601399) [12,13 & ,14 & ]: Because RUNX1 was the first HHM gene identified [15], we have a relatively long period of time following mutation-positive individuals from these families.”
BackgroundLoss of RUNX 1/ AML 1 arginine‐methylation impairs peripheral T cell homeostasis
Mizutani, S., Yoshida, T., Zhao, X., Nimer, S. D., Taniwaki, M., & Okuda, T. (2015) · British Journal of Haematology · doi:10.1111/bjh.13499 · Cited by 25
Metzeler, K. H., & Bloomfield, C. D. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-3233-2_12 · Cited by 24
Runt domains take the lead in hematopoiesis and osteogenesis
Werner, M. H., Shigesada, K., & Ito, Y. (1999) · Nature Medicine · doi:10.1038/70920 · Cited by 24
Yeast Eap1p, an eIF4E-associated protein, has a separate function involving genetic stability
Chial, H. J., Stemm-Wolf, A. J., McBratney, S., & Winey, M. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00829-0 · Cited by 24
Disruption of C/EBPα Function in Acute Myeloid Leukemia
Fröhling, S., & Döhner, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048241 · Cited by 24
Taketani, T., Taki, T., Takita, J., Ono, R., Horikoshi, Y., Kaneko, Y., Sako, M., Hanada, R., Hongo, T., & Hayashi, Y. (2002) · Leukemia · doi:10.1038/sj.leu.2402612 · Cited by 24
Three chromosomal rearrangements in neuroblastoma cluster within a 300‐kb region on 1p36.1
Spieker, N., Beitsma, M. M., Sluis, P. V., Chan, A., Caron, H. N., & Versteeg, R. (2001) · Genes Chromosomes and Cancer · doi:10.1002/gcc.1130 · Cited by 24
“Haploinsufficiency for AML1 causes familial thrombocytopenia, and haploinsufficiency for AML3 results in cleidocranial dysplasia (Lee et al., 1997; Song et al., 1999).”
BackgroundHaslam, K., Langabeer, S. E., Hayat, A., Conneally, E., & Vandenberghe, E. (2015) · British Journal of Haematology · doi:10.1111/bjh.13838 · Cited by 23
“FPD-AML kindred are defined by germ-line mutations of RUNX1 (Song et al, 1999), which encodes a transcription factor essential for definitive haematopoiesis and myeloid cell differentiation, commonly dysregulated by translocations, mutations or amplification in de novo and secondary MDS and acute…”
BackgroundInherited platelet function disorders: Diagnostic approach and management
Falcinelli, E., Bury, L., & Gresele, P. (2016) · Hämostaseologie · doi:10.5482/hamo-16-02-0002 · Cited by 23
“• Familial platelet disorder with predisposition to acute myeloid leukemia (FPD-AML) is a condition associated with autosomal dominant mutations in RUNX1, a transcription factor that functions as a master regulator of hematopoiesis, and have moderately reduced platelet count, defects of dense granule secretion and con…”
BackgroundMouse models for core binding factor leukemia
Chin, D. W. L., Watanabe‐Okochi, N., Wang, C. Q., Tergaonkar, V., & Osato, M. (2015) · Leukemia · doi:10.1038/leu.2015.181 · Cited by 23
Structural and functional characterization of Runx1, CBFβ, and CBFβ-SMMHC
Zhang, L., Lukasik, S. M., Speck, N. A., & Bushweller, J. H. (2003) · Blood Cells Molecules and Diseases · doi:10.1016/s1079-9796(03)00022-6 · Cited by 25
Self-citationPecci, A. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1351-7 · Cited by 23
“transcription complex [34].”
Etiology of Acute Myeloid Leukemia in the Elderly
Bowen, D. (2006) · Seminars in Hematology · doi:10.1053/j.seminhematol.2006.01.005 · Cited by 23
Inherited DDX41 mutations: 11 genes and counting
Tawana, K., & Fitzgibbon, J. (2016) · Blood · doi:10.1182/blood-2016-01-690909 · Cited by 23
Borst, S., Nations, C. C., Klein, J. G., Pavani, G., Maguire, J. A., Camire, R. M., Drazer, M. W., Godley, L. A., French, D. L., Poncz, M., et al. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.04.013 · Cited by 24
“Although the first case of IT with heightened risk of acute myeloid leukemia was described in 1978, heterozygous germline RUNX1 mutations were not confirmed to be the cause until 1999 (Luddy et al., 1978; Song et al., 1999).”
BackgroundSelf-citationAssessment of platelet numbers and morphology in the peripheral blood smear
Moreno, A., & Menke, D. M. (2002) · Clinics in Laboratory Medicine · doi:10.1016/s0272-2712(03)00072-6 · Cited by 23
Phosphorylation of AML1/RUNX1 Regulates Its Degradation and Nuclear Matrix Association
Biggs, J. R., Zhang, Y., Peterson, L. F., Garcia, M. V., Zhang, D., & Kraft, A. S. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-04-0184 · Cited by 30
“The 293T cells were transfected with His6-AML1c (1-230) alone, with His6-AML1c (1-230) plus hemagglutinin-ubiquitin, or with hemagglutinin-ubiqutin alone as indicated.”
BackgroundMethodInfluentialSchmit, J. M., Turner, D. J., Hromas, R., Wingard, J. R., Brown, R. A., Li, Y., Li, M. M., Slayton, W. B., & Cogle, C. R. (2015) · Leukemia Research Reports · doi:10.1016/j.lrr.2015.03.002 · Cited by 24
“Clinically, germline mutations in the RUNX1 gene cause an autosomal dominant familial platelet disorder (FPD) with propensity to transform into myeloid malignancies such as myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) [4–8].”
BackgroundRole of Germline Genetic Factors in MPN Pathogenesis
Harutyunyan, A. S., & Královics, R. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.07.005 · Cited by 22
Germline PAX5 mutations and B cell leukemia
Hyde, R. K., & Liu, P. P. (2013) · Nature Genetics · doi:10.1038/ng.2778 · Cited by 22
Odenike, O. M., Thirman, M. J., Artz, A. S., Godley, L. A., Larson, R. A., & Stock, W. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.01.010 · Cited by 27
Metadata
- Authors
- Song, W.-J., Sullivan, M. G., Legare, R. D., Hutchings, S., Tan, X., Kufrin, D., Ratajczak, J., Resende, I. C., Haworth, C., Hock, R., Loh, M., Felix, C., Roy, D.-C., Busque, L., Kurnit, D., Willman, C., Gewirtz, A. M., Speck, N. A., Bushweller, J. H., Li, F. P., Gardiner, K., Poncz, M., Maris, J. M., & Gilliland, D. G.
- Affiliations
- Brigham and Women's Hospital (US)
- Brown University (US)
- University of Pennsylvania (US)
- Leicester Royal Infirmary (GB)
- St Vincent Hospital (US)
- Hôpital Maisonneuve-Rosemont (CA)
- University of Michigan (US)
- University of New Mexico (US)
- Dartmouth College (US)
- University of Virginia (US)
- Harvard University (US)
- Roosevelt Institute (US)
- Corresponding author
- Gilliland, D. Gary
- ORCID
- Venue
- Nature Genetics
- Published
- 1999-10
- Volume
- 23
- Issue
- 2
- Pages
- 166-175
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1739103212
- Cited by
- 1,100
- References
- 49
- Citations by year
- 2026: 9 · 2025: 23 · 2024: 27 · 2023: 32 · 2022: 29 · 2021: 36 · 2020: 46 · 2019: 33 · 2018: 26 · 2017: 61 · 2016: 54 · 2015: 35 · 2014: 30 · 2013: 33 · 2012: 53
- FWCI
- 25.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (7r29ai039536-04)
- National Cancer Institute (R01CA081932, R01-CA78545, R01 CA81932, R01CA078545)
- National Institute of Allergy and Infectious Diseases (R29 AI39536)
- Topics
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Blood disorders and treatments
- Keywords
- RUNX1, haploinsufficiency, autosomal dominant inheritance, missense mutations, megakaryopoiesis, megakaryocyte colony formation, platelet disorders, chromosome 21q, nonsense mutation, intragenic deletion
- MeSH terms
- Amino Acid Sequence, Base Sequence, Blood Platelets, Chromosome Mapping, Colony-Forming Units Assay, DNA Mutational Analysis, DNA-Binding Proteins, Family Health, Female, Genotype, Hematopoiesis, Heterozygote, Humans, Male, Megakaryocytes, Molecular Sequence Data, Mutation, Pedigree, Proto-Oncogene Proteins, RNA, Sequence Homology, Nucleic Acid, Thrombocytopenia, Transcription Factors, Leukemia, Myeloid, Acute, Sequence Deletion, Sequence Homology, Amino Acid, In Situ Hybridization, Fluorescence, Microsatellite Repeats, Genetic Predisposition to Disease, Reverse Transcriptase Polymerase Chain Reaction, Core Binding Factor Alpha 2 Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.